Literature DB >> 8844876

Neuroendocrine responses to laboratory panic: cognitive intervention in the doxapram model.

J L Abelson1, J G Weg, R M Nesse, G C Curtis.   

Abstract

Doxapram is a respiratory stimulant that appears to be a potent and specific panicogenic agent. It also elicits an abnormal ventilatory response in patients with panic. A replication study confirmed these findings and demonstrated that behavioral and ventilatory responses to doxapram were significantly modified by a psychological intervention designed to cognitively block panic. The replication study provided an opportunity to simultaneously investigate the neuroendocrine effects of the illness, the drug, the drug-induced panic attacks, and the cognitive intervention. Epinephrine (EPI), norepinephrine (NE), growth hormone (GH), adrenocorticotropin (ACTH), and cortisol were studied in patients with panic and control subjects given placebo and doxapram injections after receiving either standard instructions or a brief cognitive intervention. Patients with panic had elevated levels of EPI, ACTH, and cortisol throughout the study. Doxapram had little or no detectable effects on plasma NE, GH, ACTH, and cortisol. Doxapram-induced panic attacks were not associated with elevations in NE, GH, ACTH, or cortisol. Doxapram led to a rapid and very brief rise in plasma EPI, which was small in subjects who did not panic and pronounced in patients who did panic. The cognitive intervention attenuated the EPI response to doxapram, perhaps through its effect on panic, and modified the temporal pattern of ACTH and cortisol secretion. These results suggest that: (1) further study of catecholamine responses within the first few minutes after panic induction is needed; (2) intense panic can occur without significant activation of the hypothalamic-pituitary-adrenal axis; and (3) cognitive factors can modulate neuroendocrine activity in laboratory studies of patients with panic.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844876     DOI: 10.1016/0306-4530(96)00005-4

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  5 in total

1.  Heart rate and respiratory response to doxapram in patients with panic disorder.

Authors:  Jose M Martinez; Amir Garakani; Cindy J Aaronson; Jack M Gorman
Journal:  Psychiatry Res       Date:  2015-03-09       Impact factor: 3.222

2.  Cognitive modulation of endocrine responses to CRH stimulation in healthy subjects.

Authors:  James L Abelson; Samir Khan; Elizabeth A Young; Israel Liberzon
Journal:  Psychoneuroendocrinology       Date:  2009-09-16       Impact factor: 4.905

3.  The effect of doxapram on brain imaging in patients with panic disorder.

Authors:  Amir Garakani; Monte S Buchsbaum; Randall E Newmark; Chelain Goodman; Cindy J Aaronson; Jose M Martinez; Yuliya Torosjan; King-Wai Chu; Jack M Gorman
Journal:  Eur Neuropsychopharmacol       Date:  2007-06-08       Impact factor: 4.600

4.  Lifestyle Behaviours Add to the Armoury of Treatment Options for Panic Disorder: An Evidence-Based Reasoning.

Authors:  Rod Lambert
Journal:  Int J Environ Res Public Health       Date:  2015-06-18       Impact factor: 3.390

5.  Effects of the ventilatory stimulant, doxapram on human TASK-3 (KCNK9, K2P9.1) channels and TASK-1 (KCNK3, K2P3.1) channels.

Authors:  Kevin P Cunningham; D Euan MacIntyre; Alistair Mathie; Emma L Veale
Journal:  Acta Physiol (Oxf)       Date:  2019-09-18       Impact factor: 6.311

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.